×
About 825 results

ALLMedicine™ Nail Psoriasis Center

Research & Reviews  229 results

Onychomycosis in underrepresented groups: an all of us database analysis.
https://doi.org/10.1007/s00403-022-02413-4
Archives of Dermatological Research; Moseley I, Ragi SD et. al.

Oct 20th, 2022 - Few research studies evaluating the impact of dermatologic diseases in the United States (US) have adequately included underrepresented groups. All of Us (AoU) is an ongoing precision medicine-based research initiative by the National Institutes o...

Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of...
https://doi.org/10.1111/dth.15917
Dermatologic Therapy; Gallo G, Mastorino L et. al.

Oct 11th, 2022 - Nail psoriasis is a chronic nail disorder that commonly affects psoriatic patients causing severe distress despite the limited body surface area. Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapi...

The impact of nail psoriasis on disease activity, quality of life, and clinical variabl...
https://doi.org/10.1111/1756-185X.14442
International Journal of Rheumatic Diseases; Cengiz G, Nas K et. al.

Sep 28th, 2022 - Nail involvement is common in psoriatic arthritis. This study assesses clinical characteristics, nail psoriasis prevalence, and impact of nail psoriasis on disease activity in patients with psoriatic arthritis (PsA). This cross-sectional multicent...

Uveitis and nail psoriasis in a patient without articular involvement: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509638
BMC Ophthalmology; Pineda-Sierra JS, Peña-Pulgar LF et. al.

Sep 25th, 2022 - This study aimed to report a case of bilateral anterior non-granulomatous chronic non-infectious uveitis associated with isolated nail psoriasis without articular involvement. A 55-year-old man with a history of open-angle glaucoma was referred to...

Psoriatic arthritis: one year in review 2022.
https://doi.org/10.55563/clinexprheumatol/x3sfxe
Clinical and Experimental Rheumatology; Cigolini C, Fattorini F et. al.

Sep 22nd, 2022 - Psoriatic arthritis is a systemic autoimmune disease, in which a characteristic heterogeneous inflammatory involvement of entheses and both peripheral and axial joints tends to be associated with different clinical features, in particular skin or ...

see more →

Guidelines  1 results

Treatment of nail psoriasis: best practice recommendations from the Medical Board of th...
https://doi.org/10.1001/jamadermatol.2014.2983
JAMA Dermatology; Crowley JJ, Weinberg JM et. al.

Dec 5th, 2014 - Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail psoriasis have been published. There is an unmet need for treatment recommendations to guide ...

see more →

Clinicaltrials.gov  32 results

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life
https://clinicaltrials.gov/ct2/show/NCT03774875

Sep 9th, 2022 - Participants will be randomized 2 (apremilast):1 (placebo) in approximately 10 countries in Western Europe. Participants will be block-randomized to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, ...

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03897075

Aug 29th, 2022 - Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04227288

Aug 12th, 2022 - Eligible subjects will be provided twice daily. Enstilar Foam (calcipotriene and betamethasone dipropionate). Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be ...

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03991936

Jul 21st, 2022 - This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03022617

Jul 14th, 2022 - Psoriasis vulgaris is a common inflammatory condition of the skin that results in scaly red itchy plaques. In addition to affecting the skin, psoriasis can also cause disease in the finger and toe nails. Nail psoriasis is a chronic disease and can...

see more →

News  60 results

Open Clinical Trials for Psoriasis
https://www.mdedge.com/dermatology/article/258022/psoriasis/open-clinical-trials-psoriasis

Sep 19th, 2022 - The psoriasis clinical trials listed below are all phase 3 and recruiting participants as of July 19, 2022. For additional information on the study design, eligibility criteria, and contacts/locations, visit ClinicalTrials.

Elbow tenderness and swollen joints
https://www.mdedge.com/psoriatic-arthritis-challenge-center/article/257978/psoriatic-arthritis/elbow-tenderness-and-swollen

Sep 19th, 2022 - The diagnosis for this case is psoriatic arthritis (PsA). The 2018 American College of Rheumatology/National Psoriasis Foundation guidelines offer current treatment recommendations for this condition.

Transverse Leukonychia and Beau Lines Following COVID-19 Vaccination
https://www.mdedge.com/dermatology/article/257391/covid-19-updates/transverse-leukonychia-and-beau-lines-following-covid-19
Karen Lam, BS, Elizabeth Yim, MD, MPH

Aug 26th, 2022 - To the Editor: Nail abnormalities associated with SARS-CoV-2 infection that have been reported in the medical literature include nail psoriasis,1 Beau lines,2 onychomadesis,3 heterogeneous red-white discoloration of the nail bed,4 transverse orang.

Risankizumab Effective Against Refractory Psoriatic Arthritis
https://www.medscape.com/viewarticle/966708

Jan 18th, 2022 - NEW YORK (Reuters Health) - Risankizumab, an inhibitor of interleukin 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-...

TNF-α inhibitor remains a promising therapy for nail psoriasis and concomitant PsA
https://www.mdedge.com/dermatology/article/249253/psoriatic-arthritis/tnf-inhibitor-remains-promising-therapy-nail

Dec 1st, 2021 - Key clinical point: Tumor necrosis factor (TNF)- α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA). Major finding: During the first.

see more →

Patient Education  8 results see all →